Clinigen Group plc appointed James Meyer as General Manager, Commercial Medicines, US, with immediate effect. Jim Meyer is an accomplished and seasoned executive with nearly 40 years of experience in the pharmaceutical industry, of which included five years at Teva Pharmaceuticals where he led the Oncology New Products Division in the US. Jim will be responsible for delivering on the Group’s strategy in Commercial Medicines in the US. Specifically, he has been appointed to build out Clinigen’s commercial infrastructure in the US and to capitalise on other opportunities across the business. This follows on from the acquisition of Proleukin in April 2019 which created an ideal platform to expand the Group’s existing footprint in the higher value US market where it currently owns the US rights to Foscavir, Ethyol and Totect, all of which are distributed by third parties. Jim’s appointment demonstrates the Group’s intent to build upon this opportunity.